The use of meal replacements in the obese haemodialysis patient. by Gardiner, C & Evans, A
Obesity continues to be a worldwide concern. The Health and Social Care Information Centre,
reported in 2014 that the proportion of adults in England that were overweight, including those
obese, increased between 1993 and 2012 from 57.6% to 66.6% among men and from 48.6% to
57.2% among women.1 Similar trends of obesity are being observed in the chronic kidney disease
population, with approximately 48% of our units haemodialysis population having a body mass
index (BMI) greater than 25 kg/m2. 
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The debate regarding the ‘obesity paradox’ continues, suggesting
individuals on dialysis with a higher BMI have an improved survival
and lower mortality rates. This data however may simply be
highlighting the risks associated with a low BMI.2 Nicoletto, et al.
(2014) suggested that up to the year 2000, obesity was a risk
factor for graft loss, death by cardiovascular disease and all cause
mortality after kidney transplantation. However, entering the new
millennium, it would seem that these health outcomes occur
irrespective of the individuals BMI.3 The clinical practice guidelines
published by the UK Renal Association in 2011, suggested that
though obese patients can present technical difficulties and are at
risk of increased peri-operative complications; obesity is not an
absolute contra-indication to transplantation.4 Khwaja (2012)
reported obesity may impact on long-term graft function, but its
effects are similar to other co-morbidities such as diabetes,
which is not a contra-indication for transplantation.2 The UK Renal
Association also suggest that the beneficial effects of transplantation
are lost once a BMI is greater than 40kg/m2.4
CN May 2015 Vol15 No2_2015  23/04/2015  14:43  Page 60
Obese Haemodialysis Patient  |  Special Interest
With a number of haemodialysis patients unable
to be assessed for kidney transplantation while
their weight is of a BMI greater than 40 kg/m2, the
dietitian has a role in supporting these patients
achieve safe and effective weight loss. This is
particularly important when evidence suggests
that weight loss on dialysis has demonstrated to
be a risk factor for patient death independent of
the individuals’ baseline BMI.5 Kalantr-Zadeh et al.
(2010) documented that weight loss with an
associated loss in muscle mass was associated
with the highest mortality.6 A recommended
weight loss programme needs to ensure that
weight lost is adipose tissue rather than lean body
tissue, preventing sarcopenia. However, we also
need to consider the time it takes to lose
weight, with many individuals failing to do so.
Noting the increased time on dialysis, whether
obese or not, is one of the strongest risk factors
for patient death.5
The use of meal replacements
Within our unit, we have been trialling the use
of meal replacements (MR) to aid weight loss
in those individuals with a BMI greater than
40kg/m2, who have not successfully lost weight
following diet manipulation and weight reducing
medication. MR are defined as portion-controlled
products, fortified with micronutrients, designed
to replace one or two meals a day, allowing one
meal a day using standard foods, as part of a
reduced energy diet.7 These products have been
shown to aid weight loss in a breadth of studies.
Evidence has suggested that they are safe,
efficient, cost-effective, encourage compliance as
well as ensure the total nutrient intake is sufficient
if part of a controlled programme.8 Dietitians in
Obesity Management UK (DOM UK)9 and the
American Dietetic Association10 suggest this is a
promising weight loss intervention. However no
studies have documented their use in the
haemodialysis population.
Due to other considerations, such as
potassium, phosphate and fluid, the use of
over-the-counter products may not be suitable.
Our trial used prescribed 1.5 kcal/ml and high
protein (20 g/200 ml) milk-based nutritional
supplements as the meal replacement alternative.
These products replaced two meals a day, and in
combination with one meal from standard food
and additional snacks a total 1500 kcal per day was
consumed (Figure 1). The total protein, potassium
and phosphate content of the daily programme
were calculated to meet the individuals’ needs.
Regular activity was also encouraged. 
The outcome
Within the past year, six individuals have trialled
a meal replacement programme; four of these
individuals have been using these products for
longer than six months. All patients reported that
they struggled with hunger for the first two
weeks of the MR programme. However, once that
initial period ended the patient felt hunger was
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Table One: Weight and Fluid changes of Haemodialysis Patients
on MR Programme
Weight Changes Fluid Changes
Mean results 6 months
before MR
Mean results 6 months
once MR started
Mean results 6
months before MR
Mean results 6 months
once MR started
Weight (kg) BMI (kg/m2) Weight (kg) BMI (kg/m2) IDFG (L) IDFG (L)
Patient 1 146.5 43.7 127.5 38.2 3.35 3
Patient 2 129.3 42.2 119.2 39.1 1.93 1.36
Patient 3 128 52.1 122.6 49.1 2.11 2.4
Patient 4 129.8 42.2 117.4 38.3 2 2.23
Figure 1: Example Meal Plan
Meal Calories to aim for Meal ideas - You can choose one from the list
Breakfast 300 kcal Meal replacement drink
Mid-morning 100 kcal Snack, for example: 1 cream cracker and margarine (approx. 62 kcal), 
5 bread sticks (approx. 100 kcal), Large apple 
Lunch 300 kcal Meal replacement drink
Mid-afternoon 100 kcal Snack
Evening meal 600 kcal For example: 1 medium chicken breast, boiled potatoes 100 g 
(2 large egg sized), peas 2 tbsp, sweetcorn 2 tbsp
Supper 100 kcal Snack
Table Two: Biochemical Changes of Haemodialysis Patients
on MR Programme
Serum Potassium Changes Serum Phosphate Changes
Mean results 6 months
before MR (mmol/l)
Mean results 6 months
once MR started (mmol/l)
Mean results 6 months
before MR (mmol/l)
Mean results 6 months
once MR started (mmol/l)
Patient 1 5.46 5.21 2.36 1.66
Patient 2 5.03 5.22 2.05 1.59
Patient 3 4.94 5.36 2.18 1.82
Patient 4 5.88 6.44 1.9 1.87
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Figure 2: ‘Patient 1’ Weight Changes13 
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supressed making the use of MR easier to
manage. Theim et al. (2013) conducted a 15-week
study using MR to assess the impact on behaviour
change and hedonic hunger. Although the study
was short-term, and had no control group, the
partial MR diet proved to control hedonic hunger.
The success may have been due to limited access
to foods which improved the dietary behaviour of
the patient and resulted in weight loss.11
The data we present suggests that significant
weight loss (Table One) can be achieved
when using MR, and that when following the
recommended programme biochemical markers
(Table Two) can remain safe. Inter-dialytic fluid
weight gains remain within the recommendations
of <4% actual body weight (ABW).12 ‘Patient 4’
struggled to comply with diet recommendations,
resulting in an increase in serum potassium levels;
which resulted in the patient withdrawing from
the MR programme after six months.
Bio-impedance was used on a regular basis
to ensure dry weight was reduced correctly. It was
also used to ensure weight lost was of adipose
nature rather than lean tissue. An example of this
can be seen in Figure 2, which shows the weight
changes in ‘patient 1’.  
The body composition measurement (BCM),
as shown in Figure 2, illustrates the changes in lean
tissue mass (LTM) and adipose tissue mass (ATM).13
Patient 1 commenced on the MR programme in
May 2014. The weight of the patient reduced in the
first six months, where ATM significantly declined.
BCM readings were not always taken every month.
The delay in the reduction of the patients target
weight left the patient over hydrated (OH). 
Limitations
The patients following the MR programme did
not attend the main site dialysis units. Therefore
face-to-face contact with the patients was limited.
Due to the dietitian only visiting the unit every
3-4 months we relied heavily on telephone
consultations. In addition to this, we often found  it
difficult to achieve the DOM UK guidelines,9 which
recommend reviewing the patient every two weeks. 
An MDT approach is also recommended by
the DOM UK guidelines.9 Although we strive to
work as an MDT, this is not always achievable.
All members desire the same outcome of
weight loss but, in practice, the support offered
in the individual consultation is often led by
the dietitian. Having the option of medical,
physiotherapy and psychology input may have
improved the outcome in some of these patients.
For example, the patients remained inactive
despite encouragement; a physiotherapist may
have improved this outcome.  
Though the BMI is an accepted
anthropometric measurement for obesity, it
has a limited ability to differentiate adipose tissue
from lean body tissue. Waist circumference
better reflects the intra-abdominal fat when
compared to BMI.14 Posterino et al. (2009)
documented that waist circumference is a
strong, direct, independent predictor of all-cause
and cardiovascular death.15 Although this is a
recommended outcome measure, this relates to
patients with a BMI <35 kg/m2 as the practicalities
of taking this measurement in patients with a
greater BMI is limited. We have relied on the patient
reported changes in dress size or notches on belts
as a measure of change in waist circumference.
Moving forward
The next stage is to reintroduce foods back into
the diet to replace the MR. This MR programme
has been a good education tool to show the
patient that limiting calories can result in weight
loss. We now need to invest time to ensure the
patient has confidence and support to make this
transition back to normal diet.
Summary
Meal replacements have been shown to
promote weight loss in the general population
in a safe and effective manner. The numbers of
patients we have using MR are only small. Larger
studies are required, combining inter-centre
data, to look at the outcomes of the use of MR
in the haemodialysis population.
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